Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
U.K. Academics Get Drug Firm Compounds
by Alex Scott
December 15, 2014
| A version of this story appeared in
Volume 92, Issue 50
Seven major pharmaceutical companies have given a total of 68 shelved compounds to academic researchers as part of a deal brokered by the U.K.’s Medical Research Council. U.K. scientists can apply for MRC funding to use the compounds in medical studies. The compounds were developed for treating diseases including cancer, narcolepsy, and diabetes but were rejected, often for lack of effectiveness. The seven companies are AstraZeneca, GlaxoSmithKline, Janssen, Eli Lilly & Co., Pfizer, Takeda, and UCB. MRC hopes to add more compounds as its scheme progresses.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter